A Front-Line “Window of Opportunity” Phase II Study of Sorafenib in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)– A North Central Cancer Treatment Group Study N0326()

PURPOSE: To assess the efficacy and toxicity of sorafenib as front-line therapy in patients with stage IIIB (pleural effusion) or IV NSCLC. METHODS: Patients received sorafenib 400 mg twice daily by mouth continuously, and were evaluated every 2 weeks during the first 8 weeks. Patients who manifest...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer
Main Authors: Dy, Grace K., Hillman, Shauna L., Rowland, Kendrith M., Molina, Julian R., Steen, Preston D., Wender, Donald B., Nair, Suresh, Mandrekar, Sumithra, Schild, Steven E., Adjei, Alex A.
Formato: Artigo
Idioma:Inglês
Publicado: 2010
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5725955/
https://ncbi.nlm.nih.gov/pubmed/21218460
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25448
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares